Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-NS-001 neoantigen reactive T cells in advanced NSCLC
2024-513060-26-00Phase 2Completed
- Sponsor
- Achilles Therapeutics plc
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 5
01
Overview
Phase 2, open-label trial of ATL001 and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Achilles Therapeutics plc. Primary endpoint: Frequency and severity of adverse events (AEs) and serious adverse events (SAEs). Started Jun 2024; status: completed.
02
Drugs
ATL001pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513060-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513060-26-00.